7 unknown, 6 completed, 3 recruiting, 1 active not recruiting. 10 Phase 3, 3 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Unknown 4, Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Genital Wart: new trials by email Literature Review of Genital Wart trials Research Report on Genital Wart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo - HPV Infection, HPV-Related Carcinoma | Phase 2 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 330 | 2025-01-15 | 2025-12-17 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years Placebo, 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha) - HPV Infection, HPV-Related Carcinoma | Phase 1 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 72 | 2024-08-03 | 2025-01-06 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer | Phase 3 | Active not recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 9000 | 2024-07-11 | 2024-12-12 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Placebo among 18-45 yrs, Placebo among 9-17 yrs - Penile Cancer, Anal Cancer | Phase 1 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 90 | 2022-09-23 | 2024-04-17 |
| Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Zerun HPV-9, GARDASIL ®9 - Cervical Cancer, Genital Wart | Phase 3 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 1200 | 2022-09-01 | 2022-10-28 |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine HPV Infections, Cervical Cancer Stage IIa | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 600 | 2022-05-14 | 2024-04-17 | |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
| Education, Immigration and HPV Vaccination: an Informational Randomized Trial Information T1, Information T2, Information C - Cervical Cancer, Vulvar Cancer | Not applicable | Unknown | Karolinska Institutet | 2500 | 2021-04-28 | 2021-06-11 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Genital Wart and Sexuality in Adolescence Clinical assessment - Adolescent Development, Genital Wart | Completed | Ankara City Hospital Bilkent | 90 | 2020-08-01 | 2021-03-15 | |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
| Safety and Efficacy of Laser Therapy in Gynaecology Herpes Genitalis, Genital Wart | Unknown | Juna d.o.o. | 300 | 2019-07-24 | 2019-08-30 | |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent HPV Recombinant Vaccine, Placebo - Cervical Cancers, Vulvar Cancer | Phase 1 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 90 | 2018-10-10 | 2020-01-22 |
| Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients tuberculin, cryotherapy - Genital Wart | Phase 3 | Unknown | Assiut University | 45 | 2017-06-01 | 2017-05-17 |
| Low Dose Cyclophosphamide Treats Genital Warts cyclophosphamide - Genital Wart | Phase 3 | Completed | Huazhong University of Science and Technology | 104 | 2007-01-01 | 2009-11-25 |
Condylomata Acuminata (18) · Uterine Cervical Neoplasms (10) · Papillomavirus Infections (7) · Vaginal Neoplasms (7) · Vulvar Neoplasms (6) · Anus Neoplasms (3) · Penile Neoplasms (3) · Head and Neck Neoplasms (1) · Herpes Genitalis (1) · Hidradenitis Suppurativa (1) · Lichen Sclerosus et Atrophicus (1) · Sexual Dysfunction, Physiological (1) · Uterine Cervical Dysplasia (1)
Communicable Diseases (18) · DNA Virus Infections (18) · Disease Attributes (18) · Genital Diseases (18) · Infections (18) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Sexually Transmitted Diseases (18) · Sexually Transmitted Diseases, Viral (18) · Skin Diseases (18) · Skin Diseases, Infectious (18) · Skin Diseases, Viral (18) · Skin and Connective Tissue Diseases (18) · Tumor Virus Infections (18) · Urogenital Diseases (18)
Vaccines, Synthetic (3) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Cryotherapy (1) · Cyclophosphamide (1) · Tuberculin (1)
Shanghai Bovax Biotechnology Co., Ltd. (12) · Ankara City Hospital Bilkent (1) · Assiut University (1) · Huazhong University of Science and Technology (1) · Juna d.o.o. (1) · Karolinska Institutet (1) · Shanghai Zerun Biotechnology Co.,Ltd (1)
China (14) · Slovenia (1) · Sweden (1) · Turkey (Türkiye) (1)
Ting Huang (2) · Bo Huang, PH.D, MD (1) · Jikai Zhang (1) · Lidong Gao, Master (1) · Long Sui, Doctor (1) · Yi Mo, Master (1)
PMID 10693114, PMID 10782451, PMID 11238198, PMID 12807939, PMID 15897380, PMID 16973081, PMID 18042215, PMID 19170869, PMID 20706119, PMID 23336207, PMID 25273231, PMID 26953828, PMID 27320034